Therapeutics News and Research

RSS

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB.

13 Jun 2013

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

NeuroVive Pharmaceutical AB (publ) (STO:NVP), a leading mitochondrial medicine company, has signed a collaboration agreement with Isomerase Therapeutics to develop the molecules that were recently acquired from Biotica.

12 Jun 2013

Studies demonstrate that combined therapy could destroy drug-resistant cells within melanoma tumor

Advanced metastatic melanoma is a disease that has proven difficult to eradicate. Despite the success of melanoma-targeting drugs, tumors inevitably become drug resistant and return, more aggressive than before. In the current issue of the journal Cancer Cell, however, researchers at The Wistar Institute describe how they increase the effectiveness of anti-melanoma drugs by combining anticancer therapies with diabetes drugs.

12 Jun 2013

3Care Therapeutics releases simplified nutritional program to improve patients' health

3Care Therapeutics, a manufacturer of nutritional supplements for treating common chronic health problems, announces the release of the 3Care BioSystems Program, a simplified nutritional program that helps practitioners improve patients' health and achieve thriving nutrition practices. The Program is administered via a free, easy-to-use software application; and unlike more complicated therapeutic lifestyle change programs, the 3Care Program encourages improved health outcomes through better patient compliance.

11 Jun 2013

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation.

10 Jun 2013

Nation's leading experts join forces to accelerate effective treatments for brain tumors

The nation's leading brain tumor and biotech industry experts again joined forces Friday, June 7, in a bid to accelerate more effective treatments for brain tumors and promote funding for the latest emerging therapies, as the Weill Cornell Brain and Spine Center and Voices Against Brain Cancer hosted its second annual Brain Tumor Biotech Summit.

10 Jun 2013

Researchers find new way to repair genetic defects in the skin cells of epidermolysis bullosa patients

A research team led by pediatric blood and marrow transplantation experts Mark Osborn, Ph.D. and Jakub Tolar, M.D., Ph.D. from the Masonic Cancer Center, University of Minnesota, have discovered a remarkable new way to repair genetic defects in the skin cells of patients with the skin disease epidermolysis bullosa.

10 Jun 2013

Human Argonautes directly cuts messenger RNA

Human Argonautes (hAgo), are key proteins involved in a process known as RNA interference. RNAi, as it is often called, is a mechanism that cells use to regulate gene expression.

7 Jun 2013

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life.

7 Jun 2013

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

The European Technology Platform on Nanomedicine and the NANOMED2020 project announce the publication of the White Paper on Contribution of Nanomedicine to Horizon 2020, the next European Framework Programme for Research and Innovation till 2020.

7 Jun 2013

Echo Therapeutics declares reverse split of issued and outstanding common stock

Echo Therapeutics, Inc., a company developing its needle-free Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that a 1-for-10 reverse split of the Company's issued and outstanding common stock will be effective prior to the market opening on Friday, June 7, 2013.

7 Jun 2013

Changes in normal glycan behavior lead to fatal lysosomal disease, say researchers

From the neurons that enable thought to the keratinocytes that make toenails grow-a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body.

6 Jun 2013

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Anthrax vaccines have a prominent place in the history of medicine. This goes back to, Pasteur, who while everybody associates with the milk treatment process, also worked on rabies and Anthrax vaccines in cattle.

6 Jun 2013

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple Probody-Drug Conjugates.

6 Jun 2013

BUSM researchers uncover important clues that may expand treatment options for schizophrenia

Researchers at Boston University School of Medicine have uncovered important clues about a biochemical pathway in the brain that may one day expand treatment options for schizophrenia.

6 Jun 2013

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

Echo Therapeutics, Inc., a company developing its needle-free Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is initiating a multi-center clinical trial of its Symphony CGM System to support a CE Mark Technical File for marketing approval in Europe.

5 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

A research team led by the Duke-NUS Graduate Medical School in Singapore has identified ways to inhibit the function of a key protein linked to stem cell-like behavior in terminal-stage chronic myeloid leukemia, making it possible to develop drugs that may extend the survival of these patients.

4 Jun 2013

Arcturus Therapeutics closes $1.3 M in seed funding round

Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treatment of disease, today announced it has raised $1.3 million in a seed funding round led by multiple high net-worth private investors from the United States and Canada.

3 Jun 2013

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced clinical data demonstrating the utility of VB-111's in targeted cancer treatment.

3 Jun 2013

Therapeutics News and Research

WHO issues interim policy guidance on inclusion of bedaquiline to treat adults with MDR-TB

NeuroVive signs agreement with Isomerase Therapeutics to develop and commercialize cyclophilin-inhibiting molecules

Studies demonstrate that combined therapy could destroy drug-resistant cells within melanoma tumor

3Care Therapeutics releases simplified nutritional program to improve patients' health

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Nation's leading experts join forces to accelerate effective treatments for brain tumors

Researchers find new way to repair genetic defects in the skin cells of epidermolysis bullosa patients

Human Argonautes directly cuts messenger RNA

Available drugs may have a dramatic impact on children stricken with Tay-Sachs disease

White Paper provides recommendations to create ecosystem for use of Nanomedicine in Europe

Echo Therapeutics declares reverse split of issued and outstanding common stock

Changes in normal glycan behavior lead to fatal lysosomal disease, say researchers

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

BUSM researchers uncover important clues that may expand treatment options for schizophrenia

Echo Therapeutics to evaluate safety, efficacy of Symphony CGM System in hospital setting

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Researchers identify ways to inhibit function of key protein linked to stem cell-like behavior in CML

Arcturus Therapeutics closes $1.3 M in seed funding round

Phase I/II study shows safety and efficacy of VB-111 in patients with rGBM

Industry Focus eBook - Microbiome (1st edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News